Sellbyville, DE -- (SBWIRE) -- 10/12/2018 -- The Inhalation Anesthesia Market size is set to exceed USD 1.6 billion by 2024; according to a new research report by Global Market Insights, Inc.

Market Overview:

Rising number of geriatric population coupled with increasing number of chronic diseases such as cancer, cardiovascular, neurological, and respiratory disorders and introduction of advanced anesthesia will offer lucrative growth opportunities for the inhalation anesthesia market growth.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/704

Increasing number of emergency surgeries driving the count of hospital admissions coupled with favorable private and public insurance will drive the inhalation anesthesia market. Growing investment in healthcare infrastructure development in emerging economies and increasing adoption of universal health coverage resulting in demand among public as well as private healthcare setups will propel the business growth.

Increasing number of surgeries performed in ambulatory surgical centers will stimulate business growth over the forecast years. Growing adoption of inhalation anesthesia for globally rising prevalence of cataract surgeries, enhanced access to healthcare treatments, and rise in disposable income will fuel the industry growth.

Top Key Players:

Some of the prominent players in inhalation anesthesia market are Baxter International, Hikma Pharmaceuticals, Mylan, Eisai, Halocarbon Products, Abbott, Piramal and Lunan Pharmaceutical. In September 2015, to complement with its COPD product Perforomist, Mylan with Theravance Biopharma initiated a phase lll program for Revefenacin, an antagonist having application in COPD. The approval will mark a step forward in providing more robust portfolio in the healthcare market with further enhancement of the company in nebulized respiratory market.

Regional Segmentations: -

U.S. market was valued over USD 488 million in 2016 and will grow significantly over the coming years. Rising number of plastic surgeries and substantially increasing adoption rate of the process will drive the business growth in U.S. Furthermore, presence of associations that aids in maintaining the standards of anesthesiology will fuel the industry growth in the country.

Germany accounted for highest revenue share in the region, owing to increasing chronic conditions associated with elderly population coupled with adoption rate of inhalation anesthesia. Growing prevalence of cancers and cardiovascular disorders accounting for approximately 66% of overall deaths in Germany will drive the industry growth over the forecast years.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/704

China will grow at a significant rate owing to its growing research studies in the business and high prevalence of lung cancer occurred due to pollution. Increasing use of sevoflurane and desflurane in general anesthesia pertaining to superiority of awakening afterwards surgical procedure as compared to traditional inhaled anesthetics will drive the industry growth in the country. Presence of organizations and associations offering platform for research and findings for anesthesia and mounting occurrence of chronic conditions will fuel the business growth in India.

Brazil is projected to grow at a substantial rate over the forecast period. Increasing prevalence of chronic conditions coupled with high adoption of inhalation anesthesia technique as compared to intravenous anesthesia (AVT) will stimulate business expansion in the country.